B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Executive Assistant - Precision Medicine, Bioanalysis & Translational Sciences

Full-TimePosted on 10/22/2026Deadline 11/30/26
$74.6k - $90.4k+ Discretionary incentive cash + Stock opportunities
Senior
Bachelor's, Master's, Certification
Princeton, NJ, USA
In Person
Administrative & Executive AssistanceExecutive Support
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree is required; an advanced degree or certification in administration or project management is preferred.
  • A minimum of 5–7 years of executive-level administrative support is required, preferably in a research, academic, or scientific environment; prior BMS experience and prior Executive Associate or Executive Assistant experience are strongly preferred.
  • Proven ability to prioritize and multitask, take prompt action based on departmental objectives and critical business needs, and expedite high-priority work.
  • Ability to exercise tact, diplomacy, integrity, and ethical judgment when handling confidential material and interacting with senior leaders, including research and development leadership and C-suite contacts.
  • Ability to work independently and collaboratively with administrative professionals and internal and external partners across organizational levels.
  • Ability to anticipate needs, solve problems proactively, work with limited day-to-day supervision, and remain accountable to the team.
  • Excellent written and verbal communication skills; fluency in English.
  • Strong organizational and time-management skills, with accuracy in scheduling, expense reporting, and documentation.
  • Experience supporting senior leadership in a matrixed or global organization, including business needs across time zones and periods of heavy workload.
  • Learning agility and intellectual curiosity; ability to learn new tools, systems, and processes while remaining productive in a fast-paced environment.
  • Strong proficiency in Microsoft Office Suite (Outlook, Word, Excel, and PowerPoint), SharePoint, OneDrive, and virtual collaboration tools.
  • Working knowledge of Concur Travel and T&E or related systems, Ariba/SAP, Workday, eSetup, eTime, and conference-room scheduling tools.
Responsibilities
  • Provide day-to-day administrative support to PMBATS senior leadership and support individual projects as needed, accomplishing multiple complex tasks with minimal supervision.
  • Manage dynamic calendars and timely scheduling, prioritizing meetings according to project timelines, identifying and avoiding conflicts by reviewing calendars and email, and coordinating meetings across executives and external partners.
  • Track leadership availability and absences, including summer-hours coverage, vacations, and year-end coverage, and provide backup support to Translational Medicine administrative colleagues during planned and unplanned absences.
  • Arrange domestic and international travel itineraries, including visas where required, to optimize efficiency; coordinate congress attendance and track attendance updates.
  • Manage leaders’ personal expenses in Concur, including credit card and cash inquiries, receipt claims, and monthly reconciliation, ensuring compliance with travel and expense policies, Sarbanes-Oxley, Sunshine Act requirements, and company policies.
  • Prepare leaders for meetings by assembling materials, assisting with PowerPoint presentations and document formatting, and coordinating pre-reads and preparatory meetings with key stakeholders.
  • Conserve executive time by reading, researching, and routing correspondence; drafting letters and documents; collecting and analyzing information; and independently researching complex inquiries, responding or escalating with recommended solutions as appropriate.
  • Schedule and organize group events and other meetings.
  • Organize administrative systems for department members, including OneDrive and SharePoint, filing and records retention, supply requisitions, access management for staff inside and outside the department, and resolution of IT, systems, and facilities requests.
  • Provide human-resources and facilities support, including interview organization, new-hire processes, onboarding, Staffing Database updates, and creation, editing, and tracking of job requisitions in Workday.
  • Support the team with budget change requests and study-number requests as workstream owner.
  • Partner proactively with matrix teams, including Finance, Operations, HR business partners, and People Services, to facilitate projects, tasks, and meetings.
  • Maintain professional and technical knowledge by staying current with company continuous-learning modules.
Desired Qualifications
  • An advanced degree or certification in administration or project management is preferred.
  • Executive-level administrative support experience in a research, academic, or scientific environment is preferred.
  • Prior BMS experience and prior Executive Associate or Executive Assistant experience are strongly preferred.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8